Metzger Michael A

CIK 00015072205 companiesLOS ANGELES, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001507220

Recent Transactions

50 trades

Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-09-08$10.90/sh+157,307→ 455,968 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock options (Right to buy)
2025-09-08+157,307→ 0 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-09-08$16.41/sh−157,307→ 298,661 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-07-16$9.29/sh−7,534→ 298,661 total
Award
Pyxis Oncology, Inc.$PYXS
Stock Option (Right to Buy)
2025-03-31$0.98/sh+36,979→ 36,979 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-03-14$7.20/sh+6,074→ 306,195 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock options (Right to buy)
2025-03-14+6,074→ 0 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-03-04$15.05/sh−7,814→ 300,121 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock options (Right to buy)
2025-03-04+7,814→ 0 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-03-04$7.20/sh+7,814→ 307,935 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-02-10$15.50/sh−13,288→ 300,121 total
Award
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2025-02-05$14.65/sh+364,000→ 364,000 total
Award
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-02-05+60,500→ 224,409 total
Award
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2025-02-05+89,000→ 313,409 total
Award
Pyxis Oncology, Inc.$PYXS
Stock Option (Right to Buy)
2024-06-10+70,683→ 70,683 total
Award
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2024-02-07+107,250→ 124,909 total
Award
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2024-02-07$22.28/sh+214,500→ 214,500 total
Award
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2024-02-07+39,000→ 163,909 total
Disposition to Issuer
CTI BIOPHARMA CORP
Stock Option (Right to Buy)
2023-06-26−63,000→ 0 total
Disposition to Issuer
CTI BIOPHARMA CORP
Stock Option (Right to Buy)
2023-06-26−80,000→ 0 total
Disposition to Issuer
CTI BIOPHARMA CORP
Stock Option (Right to Buy)
2023-06-26−80,000→ 0 total
Disposition to Issuer
CTI BIOPHARMA CORP
Stock Option (Right to Buy)
2023-06-26−80,000→ 0 total
Disposition to Issuer
CTI BIOPHARMA CORP
Stock Option (Right to Buy)
2023-06-26−60,000→ 0 total
Disposition to Issuer
CTI BIOPHARMA CORP
Stock Option (Right to Buy)
2023-06-26−50,000→ 0 total
Award
CTI BIOPHARMA CORP
Stock Option (right to buy)
2023-04-05+80,000→ 80,000 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2023-02-06$27.64/sh−5,959→ 17,659 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2023-02-06$6.38/sh+5,959→ 23,618 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2023-02-06$27.64/sh−5,959→ 0 total
Award
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2023-02-02$28.55/sh+410,000→ 410,000 total
Exercise/Conversion
CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
2022-11-08−63,000→ 63,000 total
Exercise/Conversion
CTI BIOPHARMA CORP
common stock
2022-11-08$1.00/sh+63,000→ 91,500 total
Sale
CTI BIOPHARMA CORP
common stock
2022-11-08$5.65/sh−36,942→ 4,500 total
Sale
CTI BIOPHARMA CORP
common stock
2022-11-08$5.53/sh−50,058→ 41,442 total
Exercise/Conversion
CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
2022-11-08−28,500→ 0 total
Exercise/Conversion
CTI BIOPHARMA CORP
common stock
2022-11-08$0.84/sh+28,500→ 28,500 total
Sale
CTI BIOPHARMA CORP
common stock
2022-11-08$5.70/sh−4,500→ 0 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-10-06$25.29/sh−16,231→ 17,659 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-10-06$8.77/sh+16,231→ 33,890 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2022-10-06−16,231→ 0 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-10-04$25.02/sh−1,280→ 17,659 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-10-04$8.77/sh+1,280→ 18,939 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2022-10-04−1,280→ 0 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2022-10-03−2,883→ 0 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-10-03$8.77/sh+2,883→ 20,542 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-10-03$25.01/sh−2,883→ 17,659 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-09-30$8.77/sh+29,606→ 47,265 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2022-09-30−29,606→ 0 total
Sale
Syndax Pharmaceuticals Inc$SNDX
Common Stock
2022-09-30$25.02/sh−29,606→ 17,659 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2022-07-25−11,838→ 0 total
Exercise/Conversion
Syndax Pharmaceuticals Inc$SNDX
Stock Options (Right to buy)
2022-07-25−19,764→ 0 total

Companies

Recent Filings

Address

C/O RESPONSE GENETICS, INC 1640 MARENGO ST., 6TH FLOOR

LOS ANGELES, CA, 90033

View on SEC.gov